{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:29:41Z","timestamp":1790141381806,"version":"4.0.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.04.027","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:59:35Z","timestamp":1777733975000},"page":"1051.e1-1051.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT"],"prefix":"10.1016","volume":"32","author":[{"given":"Stella M.","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0797-111X","authenticated-orcid":false,"given":"John","family":"Craddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-3226","authenticated-orcid":false,"given":"Parastoo B.","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-1766","authenticated-orcid":false,"given":"David","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2056-5167","authenticated-orcid":false,"given":"Michael B.","family":"Grimley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8323-3085","authenticated-orcid":false,"given":"Michael D.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1779-7358","authenticated-orcid":false,"given":"Ruby","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1669-0355","authenticated-orcid":false,"given":"Amanda L.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1934-2954","authenticated-orcid":false,"given":"Jeremy D.","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah McCormack","family":"Spivey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridoula","family":"Vasileiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Prockop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7049-7698","authenticated-orcid":false,"given":"Helen E.","family":"Heslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5067","key":"10.1016\/j.jtct.2026.04.027_bib0001","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.jtct.2026.04.027_bib0002","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2016-01-628982","article-title":"T cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.027_bib0003","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1172\/JCI90599","article-title":"Immunotherapy for transplantation-associated viral infections","volume":"127","author":"Roddie","year":"2017","journal-title":"J Clin Invest"},{"issue":"17","key":"10.1016\/j.jtct.2026.04.027_bib0004","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/bloodadvances.2019000371","article-title":"\"Mini\" bank of only 8 donors supplies CMV-directed T cells to diverse recipients","volume":"3","author":"Tzannou","year":"2019","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.jtct.2026.04.027_bib0005","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/bloodadvances.2021004456","article-title":"Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted","volume":"5","author":"Rubinstein","year":"2021","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.jtct.2026.04.027_bib0006","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1182\/bloodadvances.2022007103","article-title":"Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant","volume":"6","author":"Jiang","year":"2022","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.jtct.2026.04.027_bib0007","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1200\/JCO.20.02608","article-title":"Third-party BK virus-specific cytotoxic T lymphocyte therapy for hemorrhagic cystitis following allotransplantation","volume":"39","author":"Olson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Sullp 1","key":"10.1016\/j.jtct.2026.04.027_bib0008","first-page":"S2","article-title":"A phase II study of cellular adoptive immunotherapy with donor-derived CMV-specific T-cell clones as prophylaxis for CMV disease in allogeneic HCT recipients","volume":"39","author":"Boeckh","year":"2007","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.027_bib0009","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting","volume":"29","author":"Pfeiffer","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.jtct.2026.04.027_bib0010","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1182\/bloodadvances.2023011562","article-title":"Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients","volume":"8","author":"Dadwal","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.027_bib0011","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","volume":"25","author":"Mahadeo","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.027_bib0012","first-page":"12","article-title":"ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients","volume":"73","author":"Cesaro","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jtct.2026.04.027_bib0013","article-title":"Management of BK virus-associated haemorrhagic cystitis in allogeneic stem cell transplant recipients","volume":"8","author":"Jandial","year":"2021","journal-title":"Ther Adv Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.027_bib0014","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bbmt.2015.12.009","article-title":"Cidofovir in the treatment of BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Philippe","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.027_bib0015","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.bbmt.2018.04.009","article-title":"Efficacy of cidofovir in treatment of BK virus-induced hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients","volume":"24","author":"Coomes","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.027_bib0016","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1093\/cid\/ciz1194","article-title":"The natural history of BK polyomavirus and the host immune response after stem cell transplantation","volume":"71","author":"Laskin","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"31","key":"10.1016\/j.jtct.2026.04.027_bib0017","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.jtct.2026.04.027_bib0018","first-page":"5745","article-title":"Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients","volume":"4","author":"Nelson","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.027_bib0019","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.bbmt.2014.04.017","article-title":"Relationship of BK polyoma virus (BKV) in the urine with hemorrhagic cystitis and renal function in recipients of T cell-depleted peripheral blood and cord blood stem cell transplantations","volume":"20","author":"Lee","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.027_bib0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.027_bib0021","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00401-015-1471-7","article-title":"Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS)","volume":"130","author":"Bauer","year":"2015","journal-title":"Acta Neuropathol"},{"issue":"17","key":"10.1016\/j.jtct.2026.04.027_bib0022","doi-asserted-by":"crossref","first-page":"11170","DOI":"10.1128\/JVI.79.17.11170-11178.2005","article-title":"Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides","volume":"79","author":"Krymskaya","year":"2005","journal-title":"J Virol"},{"issue":"Pt 10","key":"10.1016\/j.jtct.2026.04.027_bib0023","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1099\/vir.0.82094-0","article-title":"T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus","volume":"87","author":"Li","year":"2006","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.027_bib0024","doi-asserted-by":"crossref","first-page":"116.e1","DOI":"10.1016\/j.jtct.2021.11.005","article-title":"Off-the-shelf third-party virus-specific T cell therapy to treat JC polyomavirus infection in hematopoietic stem cell transplantation recipients","volume":"28","author":"Rubinstein","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"15","key":"10.1016\/j.jtct.2026.04.027_bib0025","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","article-title":"Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy","volume":"379","author":"Muftuoglu","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.027_bib0026","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ana.26020","article-title":"Adoptive transfer of JC virus-specific T lymphocytes for the treatment of progressive multifocal leukoencephalopathy","volume":"89","author":"Berzero","year":"2021","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.027_bib0027","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1212\/NXI.0000000000001020","article-title":"Allogeneic BK virus-specific T-cell treatment in 2 patients with progressive multifocal leukoencephalopathy","volume":"8","author":"Hopfner","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.027_bib0028","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3390\/v17070934","article-title":"Adoptive JC virus-specific T lymphocytes for the treatment of progressive multifocal leukoencephalopathy: experience from two Italian centers","volume":"17","author":"Pocora","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.jtct.2026.04.027_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241253917","article-title":"Combined treatment with allogeneic Epstein-Barr- and human polyomavirus 1 specific T-cells in progressive multifocal leukoencephalopathy and EBV infection: a case report","volume":"17","author":"Nay","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.027_bib0030","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/jamaneurol.2024.3324","article-title":"Directly isolated allogeneic virus-specific T cells in progressive multifocal leukoencephalopathy","volume":"81","author":"Mohn","year":"2024","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.027_bib0031","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.bbmt.2014.03.018","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation is associated with selective control of JC virus reactivation","volume":"20","author":"Tan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"10.1016\/j.jtct.2026.04.027_bib0032","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.027_bib0033","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jtct.2025.06.025","article-title":"American Society for Transplantation and Cellular Therapy Series #11: Updated cytomegalovirus guidelines in hematopoietic cell transplant and cellular therapy recipients","volume":"31","author":"Khawaja","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.027_bib0034","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American Society for Transplantation and Cellular Therapy Series: #3\u2014Prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.027_bib0035","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jtct.2021.09.010","article-title":"American Society for Transplantation and Cellular Therapy Series: #4 \u2013 Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation","volume":"27","author":"Yong","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.027_bib0036","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","article-title":"Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Micklethwaite","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.027_bib0037","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2008-06-161695","article-title":"Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation","volume":"112","author":"Micklethwaite","year":"2008","journal-title":"Blood"},{"issue":"9393","key":"10.1016\/j.jtct.2026.04.027_bib0038","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(03)14634-X","article-title":"Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines","volume":"362","author":"Peggs","year":"2003","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.027_bib0039","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1086\/648422","article-title":"Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation","volume":"49","author":"Peggs","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.027_bib0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/ciq042","article-title":"Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation","volume":"52","author":"Peggs","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.027_bib0041","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.jtct.2026.04.027_bib0042","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"issue":"242","key":"10.1016\/j.jtct.2026.04.027_bib0043","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.027_bib0044","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bbmt.2015.05.015","article-title":"Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia","volume":"21","author":"Koehne","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.027_bib0045","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1182\/bloodadvances.2021006309","article-title":"Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant","volume":"6","author":"Rubinstein","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.027_bib0046","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jtct.2023.01.027","article-title":"Third-party and patient-specific donor-derived virus-specific T cells demonstrate similar efficacy and safety for management of viral infections after hematopoietic stem cell transplantation in children and young adults","volume":"29","author":"Galletta","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"24","key":"10.1016\/j.jtct.2026.04.027_bib0047","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.027_bib0048","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/CJI.0000000000000197","article-title":"Early experience with CliniMACS prodigy CCS (IFN-gamma) system in selection of virus-specific T cells from third-party donors for pediatric patients with severe viral infections after hematopoietic stem cell transplantation","volume":"41","author":"Kallay","year":"2018","journal-title":"J Immunother"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.027_bib0049","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13584","article-title":"Successful treatment of post-transplant CMV meningoencephalitis with third-party CMV virus-specific T cells: lessons learned","volume":"23","author":"Alonso","year":"2019","journal-title":"Pediatr Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.027_bib0050","doi-asserted-by":"crossref","first-page":"e165476","DOI":"10.1172\/JCI165476","article-title":"Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant","volume":"133","author":"Prockop","year":"2023","journal-title":"J Clin Invest"},{"issue":"26","key":"10.1016\/j.jtct.2026.04.027_bib0051","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.04.027_bib0052","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025017097","article-title":"Outcomes with third party virus specific T-cells after the use of single antigen cell lines to predict HLA restriction","author":"Rubinstein","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.027_bib0053","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1038\/s41467-024-47057-2","article-title":"Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment","volume":"15","author":"Keller","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2026.04.027_bib0054","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.70136","article-title":"Adoptive transfer of third-party donor CMV-specific T cells for refractory cytomegalovirus infection following umbilical cord blood transplantation","author":"Sun","year":"2025","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.027_bib0055","article-title":"Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years","volume":"15","author":"Meller","year":"2024","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.027_bib0056","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood-2014-06-573725","article-title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HCT","volume":"125","author":"Feucht","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.027_bib0057","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jaci.2016.03.032","article-title":"Specific T cells for the treatment of cytomegalovirus and\/or adenovirus in the context of hematopoietic stem cell transplantation","volume":"138","author":"Creidy","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"19","key":"10.1016\/j.jtct.2026.04.027_bib0058","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","article-title":"Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation","volume":"114","author":"Leen","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.027_bib0059","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1016\/j.jtct.2025.01.339","article-title":"Outcome analysis post virus-specific T cell therapy for the treatment of adenoviremia in immunocompromised pediatric patients","volume":"31","author":"Djassemi","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.027_bib0060","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1249","article-title":"Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant","volume":"10","author":"Gottlieb","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.jtct.2026.04.027_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.567020","article-title":"Management of PTLD after hematopoietic stem cell transplantation: immunological perspectives","volume":"11","author":"Compagno","year":"2020","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.jtct.2026.04.027_bib0062","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.386","article-title":"Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia","volume":"43","author":"Styczynski","year":"2009","journal-title":"Bone Marrow Transplant,"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.027_bib0063","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.027_bib0064","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.bbmt.2015.07.035","article-title":"Epstein-Barr virus-related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes","volume":"21","author":"Xu","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.027_bib0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bbmt.2009.10.008","article-title":"Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation","volume":"16","author":"Blaes","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.027_bib0066","doi-asserted-by":"crossref","first-page":"43.e1","DOI":"10.1016\/j.jtct.2022.10.013","article-title":"Rituximab toxicity after preemptive or therapeutic administration for post-transplant lymphoproliferative disorder","volume":"29","author":"Kinzel","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.027_bib0067","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.027_bib0068","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.027_bib0069","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.jtct.2026.04.027_bib0070","article-title":"Banked EBV-specific T-cells from HLA-partially matched normal donors to induce durable remissions of rituximab refractory EBV+B-cell lymphomas post hematopoietic and organ allografts","volume":"33","author":"Prockop","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2026.04.027_bib0071","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/jpids\/piad077","article-title":"Virus-specific T cells for the treatment of systemic infections following allogeneic hematopoietic cell and solid organ transplantation","volume":"13","author":"Green","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.027_bib0072","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.027_bib0073","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/bloodadvances.2023010832","article-title":"Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children\u2019s Oncology Group study","volume":"8","author":"Wistinghausen","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.027_bib0074","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cid\/ciy549","article-title":"Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label phase I clinical trial","volume":"68","author":"Smith","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.027_bib0075","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.ajt.2024.04.009","article-title":"Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant","volume":"24","author":"Khoury","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jtct.2026.04.027_bib0076","unstructured":"AlloVir. Study of posoleucel (ALVR105, Viralym-M) for multi-virus prevention in patients post-allogeneic hematopoietic cell transplant (prevent). 2024; Available from: https:\/\/clinicaltrials.gov\/study\/NCT05305040."},{"key":"10.1016\/j.jtct.2026.04.027_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.801281","article-title":"Case report: fatal complications of BK virus-hemorrhagic cystitis and severe cytokine release syndrome following BK virus-specific T-cells","volume":"12","author":"Holland","year":"2021","journal-title":"Front Immunol"},{"issue":"18","key":"10.1016\/j.jtct.2026.04.027_bib0078","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1073\/pnas.96.18.10391","article-title":"Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease","volume":"96","author":"Khanna","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.027_bib0079","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41467-024-47056-3","article-title":"Secondary bone marrow graft loss after third-party virus-specific T cell infusion: case report of a rare complication","volume":"15","author":"Keller","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.027_bib0080","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41409-023-01962-0","article-title":"Role of hospital exemption in Europe: position paper from the Spanish advanced therapy network (TERAV)","volume":"58","author":"Sanchez-Guijo","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.027_bib0081","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.40","article-title":"On behalf of the SFGM-TC: real-life use of third-party virus-specific T-cell transfer in immunocompromised transplanted patients","volume":"8","author":"Leroyer","year":"2024","journal-title":"Hemasphere"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:00:03Z","timestamp":1788552003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666636726003143"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.027","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}